Target intelligence / Profile preview

HLA-E:NKG2A Interaction Blockade

Molecular classification: Immune checkpoint

Overview

Blockading the interaction between NKG2A and its ligand HLA‑E removes an important brake from innate and adaptive cytotoxic lymphocytes. This approach holds significant promise for improving outcomes across multiple malignancies where tumors exploit this pathway for immune escape. Ongoing clinical trials will further clarify its therapeutic value in oncology settings.

Other names: CD159a:CD94-Human Leukocyte Antigen ENKG2A-Human Leukocyte Antigen E axis

Mechanism of action

Disrupts the interaction between HLA-E and NKG2A, enhancing NK cell and CD8+ T cell activity.

Biological functions

Immune responseNegative regulation via ITIM signaling

Disease associations

CancerImmune evasion

Interacting drugs

Monalizumab

2 more in the full profile.

Beyond the preview

Go deeper on HLA-E:NKG2A Interaction Blockade.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA-E:NKG2A Interaction Blockade.

Explore the full profile